{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:25:52Z","timestamp":1782746752980,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.neurol.2017.03.020","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T19:46:00Z","timestamp":1493408760000},"page":"388-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Expression of receptor for advanced glycation end-products (RAGE) in thymus from myasthenia patients"],"prefix":"10.1016","volume":"173","author":[{"given":"M.","family":"Bouchikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zouaidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.H.A.","family":"Benhaddou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mahassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Achir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.O.","family":"El Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2017.03.020_bib0130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.0000137876.28454.64","article-title":"Protein glycation: a firm link to endothelial cell dysfunction","volume":"95","author":"Wautier","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.neurol.2017.03.020_bib0135","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2017.03.020_bib0140","doi-asserted-by":"crossref","first-page":"e403460","DOI":"10.1155\/2013\/403460","article-title":"Receptor for advanced glycation end products and its involvement in inflammatory diseases","volume":"2013","author":"Chuah","year":"2013","journal-title":"Int J Inflamm"},{"key":"10.1016\/j.neurol.2017.03.020_bib0145","first-page":"985","article-title":"RAGE in inflammation: a new therapeutic target?","volume":"7","author":"Bierhaus","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.neurol.2017.03.020_bib0150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pharma.2014.05.002","article-title":"Les produits de glycation avanc\u00e9e: un risque pour la sant\u00e9 humaine","volume":"72","author":"Wautier","year":"2014","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.neurol.2017.03.020_bib0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1479-5876-7-17","article-title":"RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation","volume":"7","author":"Sparvero","year":"2009","journal-title":"J Transl Med"},{"key":"10.1016\/j.neurol.2017.03.020_bib0160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/cclm-2013-0578","article-title":"Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?","volume":"52","author":"Marinakis","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.neurol.2017.03.020_bib0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.revmed.2013.09.012","article-title":"Myasth\u00e9nie et auto-anticorps: physiopathologie des diff\u00e9rentes entit\u00e9s","volume":"35","author":"Berrih-Aknin","year":"2014","journal-title":"Rev M\u00e9decine Interne"},{"key":"10.1016\/j.neurol.2017.03.020_bib0170","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.neurol.2013.01.625","article-title":"Thymoma-associated myasthenia gravis: clinical features and surgical results","volume":"169","author":"Bouchikh","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2017.03.020_bib0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2017.03.020_bib0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards1","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.neurol.2017.03.020_bib0185","doi-asserted-by":"crossref","first-page":"e94118","DOI":"10.1371\/journal.pone.0094118","article-title":"Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology","volume":"9","author":"Moser","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.neurol.2017.03.020_bib0190","first-page":"445","article-title":"Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer","volume":"10","author":"Kuniyasu","year":"2003","journal-title":"Oncol Rep"},{"key":"10.1016\/j.neurol.2017.03.020_bib0195","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","article-title":"RAGE ligation affects T cell activation and controls T cell differentiation","volume":"181","author":"Chen","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0200","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.4049\/jimmunol.174.12.7506","article-title":"Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products","volume":"174","author":"Dumitriu","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0205","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.4049\/jimmunol.179.12.8051","article-title":"Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo","volume":"179","author":"Moser","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0210","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2012.02.121","article-title":"The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis","volume":"420","author":"Moser","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.neurol.2017.03.020_bib0215","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2796.2011.02432.x","article-title":"High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus","volume":"270","author":"Urbonaviciute","year":"2011","journal-title":"J Intern Med"},{"key":"10.1016\/j.neurol.2017.03.020_bib0220","doi-asserted-by":"crossref","first-page":"R817","DOI":"10.1186\/ar1749","article-title":"Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control","volume":"7","author":"Pullerits","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.neurol.2017.03.020_bib0225","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clim.2011.04.013","article-title":"Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms","volume":"141","author":"Mu","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/smim.1998.0155","article-title":"Fas\/APO-1\/CD95 in health and autoimmune disease: thymic and peripheral aspects","volume":"10","author":"Moulian","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0235","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0896-8411(89)90267-9","article-title":"High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes from patients with myasthenia gravis: correlations with clinical parameters","volume":"2","author":"Cohen-Kaminsky","year":"1989","journal-title":"J Autoimmun"},{"key":"10.1016\/j.neurol.2017.03.020_bib0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-5728(94)90080-9","article-title":"Augmented interferon-\u03b3, interleukin-4 and transforming growth factor-\u03b2 mRNA expression in blood mononuclear cells in myasthenia gravis","volume":"51","author":"Link","year":"1994","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.12.001","article-title":"Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis","volume":"256","author":"Luo","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2017.03.020_bib0250","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann N Y Acad Sci"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537871630220X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537871630220X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T03:50:56Z","timestamp":1535860256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537871630220X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S003537871630220X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2017.03.020","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of receptor for advanced glycation end-products (RAGE) in thymus from myasthenia patients","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2017.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}